This study is evaluating how safe and tolerable a new targeted therapy is (called PRT2527) when given alone, and in combination with another targeted therapy (called zanubrutinib), in people with certain relapsed or refractory blood cancersA Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With Relapsed/Refractory Hematologic Malignancies

Exclusion

• Have active central nervous system involvement by malignancy, uncontrolled intercurrent illnesses, and active infections requiring systemic therapy
• Have undergone HSCT within the last 90 days or have graft versus host disease (GvHD) Grade > 1 at study entry
• Mean corrected QT interval of > 470 msec following triplicate ECG measurements or a history of long QT Syndrome
• Have severe pulmonary disease with hypoxemia
• History of another malignancy except for adequately treated non-melanoma skin cancer or lentigo maligna, superficial bladder cancer, and carcinoma in situ of the cervix without evidence of disease, and asymptomatic prostate cancer without known metastatic disease and no requirement for therapy
• Concurrent treatment or within 15 days of starting study treatment with strong CYP3A4 inhibitors or inducers or use of moderate CYP3A4 inducers (for combination therapy only)
• Prior exposure to a CDK9 inhibitor
• Wait at least 5 half-lives of the agent or 14 days after their investigational or approved therapies before start of study treatment, whichever is shorter
• Mean corrected QT interval of > 470 msec following triplicate ECG measurement or history of long QT syndrome
• T-Cell leukemias